Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR) (NIS-TAVI-AMY)
Degenerative aortic stenosis (AS) is frequently accompanied by left ventricular hypertrophy and diastolic dysfunction, features that overlap with transthyretin (ATTR) cardiac amyloidosis. Because concomitant cardiac amyloidosis may adversely affect outcomes after transcatheter aortic valve implantation (TAVI), its early detection is clinically important.
This prospective observational study aims to evaluate multimodal imaging biomarkers for the detection and characterization of cardiac amyloidosis in patients with severe AS undergoing TAVI evaluation. Clinically indicated technetium-99m phosphonate SPECT/CT and CT will be used to assess the presence and extent of cardiac amyloidosis, including quantitative measures of myocardial tracer uptake and extracellular volume. In patients with abnormal findings, cardiac magnetic resonance imaging (CMR) will be performed as an additional non-invasive imaging modality according to institutional clinical practice.
The study will determine the prevalence of cardiac amyloidosis in this population and investigate the diagnostic and prognostic value of imaging-derived quantitative parameters. Standardized clinical follow-up at 6, 12, and 24 months will assess associations between imaging biomarkers and clinical outcomes. The study is observational and does not alter routine clinical management or diagnostic pathways.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Degenerative aortic valve stenosis (AS) is currently the most common heart valve disease in western countries. It is defined as aortic valve opening area <1.0cm² and/or an average gradient of 40mmHg. Elderly patients with higher-grade AS are primarily treated interventionally by means of transcatheter aortic valve implantation (TAVI). The outcome here does not seem to be any worse compared to conventional/cardiac aortic valve replacement. A hallmark of higher grade AS is left ventricular hypertrophy. In addition, there is often a restrictive filling pattern, which can be demonstrated in echocardiography. These characteristics are also found in cardiac amyloidosis of the TTR type (transthyretin type). Amyloid was found in over 70% of surgically removed heart valves in patients who received an aortic valve replacement. The detection of amyloid is of clinical importance for the patient, since there are different therapeutic approaches depending on the respective amyloid form. Endomyocardial biopsy (EMB) is currently the gold standard for the detection of cardiac amyloidosis in many places. However, it is an invasive procedure with associated risks and limitations (e.g. sampling error). Cardiac amyloidosis can be recognized non-invasively by the calcium-associated storage of technetium 99m (Tc99m)-labelled phosphonates, as is traditionally used in skeletal scintigraphy. According to the previous data, Tc99m phosphonate scintigraphy using SPECT/CT has a high specificity for the detection of TTR amyloidosis. If a SPECT/CT is available, this non-invasive diagnostic procedure is preferred to EMB.
The previous data indicate a correlation between the prognosis and the phosphonate storage in the myocardium. Using the Perugini score, the tracer uptake is only classified as a discrete size in a rough grid. A quantification of myocardial radiopharmaceutical intake could provide quantitative parameters that not only better reflect the severity of cardiac amyloidosis, but could also serve as a prognostic parameter. Such a quantification could take place through hybrid imaging using SPECT/CT, in which the anatomical information from computer tomography (CT) is combined with the functional information from single photon emission tomography (SPECT). This quantification takes place in a post-processing of the acquired data sets.
In addition to Tc99-SPECT/CT, cardiac MRI (CMR) with its excellent tissue characterization can also display inflammatory and fibrotic changes in the heart muscle, as can occur in amyloidosis as part of protein deposition. In addition to the established late gadolinium enhancement (LGE) technique, which can primarily map focal fibrotic processes with high accuracy, current CMR techniques for tissue characterization (T1/T2 mapping) can also be used to quantify diffuse myocardial changes, and distinguish fibrotic from inflammatory changes of the heart muscle by T1 or T2 weighting. If the Tc99-SPECT/CT findings are noticeable, a subsequent CMR is carried out for verification at the UKT as standard. This is the case in approximately 10% of patients.
If early detection of cardiac amyloidosis is assured, the clinical course of the patient could possibly be positively influenced by timely adequate therapy.
The aim of this study is to first determine the prevalence of cardiac amyloidosis using SPECT/CT and, if available, to quantify it. In patients with conspicuous SPECT/CT, the multimodal CMR is then (still) more likely to make possible cardiac amyloidosis as a second non-invasive method. The standardized follow-up after 6 or 12/24 months is planned to check the parameters determined by imaging technology (Tc99-SPECT/CT (or CMR)) for their prognostic relevance.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Patrick Krumm, Prof. Dr. med.
- Phone Number: +49 7071 29 68119
- Email: patrick.krumm@med.uni-tuebingen.de
Study Contact Backup
- Name: Studienzentrum Bildgebung Radiology
- Phone Number: +49 7071 29 85251
- Email: studienzentrum-radiologie@med.uni-tuebingen.de
Study Locations
-
-
-
Tübingen, Germany, 72076
- Recruiting
- University Hospital of Tuebingen
-
Contact:
- Jan M. Brendel, PD Dr. med.
- Phone Number: +49 7071 29 68528
- Email: jan.brendel@med.uni-tuebingen.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with severe aortic valve stenosis (valve opening area <1 cm², pmean >40 mmHg, Vmax >4 m/sec)
- Suspected cardiac amyloidosis
- Performance of one or more of the following imaging examinations due to (justifiable) clinical indication: echocardiography, photon-counting computed tomography (CT), Tc99-SPECT/CT, cardiac MRI
- Age ≥18 years
- Written consent of the patient for prospective data collection regarding Tc99-SPECT/CT, CT, and, if applicable, CMR and follow-up
Exclusion Criteria:
• patients unable to give consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients with higher grade aortic stenosis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants Diagnosed with Cardiac Amyloidosis
Time Frame: At baseline
|
Presence of cardiac amyloidosis as determined by the study imaging protocol and diagnostic criteria.
The prevalence will be reported as the proportion of participants diagnosed with cardiac amyloidosis among patients with severe aortic valve stenosis.
|
At baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Experiencing Adverse Cardiac Events
Time Frame: Up to 2 years after enrollment
|
Occurrence of major adverse cardiovascular events during follow-up.
The prognostic value of the imaging examinations will be assessed.
|
Up to 2 years after enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Patrick Krumm, Prof. Dr. med., University Hospital of Tuebingen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Aortic Valve Disease
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Heart Diseases
- Neuromuscular Diseases
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Peripheral Nervous System Diseases
- Neurodegenerative Diseases
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Heredodegenerative Disorders, Nervous System
- Proteostasis Deficiencies
- Coronary Disease
- Myocardial Ischemia
- Amyloid Neuropathies
- Amyloidosis, Familial
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Aortic Valve Stenosis
- Constriction, Pathologic
- Coronary Stenosis
- Amyloidosis
- Amyloid Neuropathies, Familial
Other Study ID Numbers
Other Study ID Numbers
- 766/2019BO2
- DRKS00020481 (Other Identifier: DRKS, German Clinical Trials Register)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.